Locations:
Search IconSearch
June 18, 2019/Neurosciences

Identifying Risks Factors Associated With Extended Length of Stay in Posterior Segmental Instrumented Fusion for Adolescent Idiopathic Scoliosis

Effective pain relief and major postoperative complications correlate with length of stay, study finds

Goodwin, MD

The use of epidural analgesia (EA) may be a protective factor against extended length of stay (LLOS) in patients undergoing posterior segmental instrumented fusion (PSIF) for adolescent idiopathic scoliosis (AIS).

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

A retrospective cohort study, recently published in the journal Spine Deformity, analyzed a variety of demographic and surgical factors in order to identify independent risk factors associated with increased LOS. The two factors most strongly associated with LLOS were major postoperative complications and the use of EAs for pain management. Other factors with statistically significant correlations were female sex, ≥9 ±2 levels of fusion, amount of operative blood loss, major postoperative complications, lack of EA and higher thoracic kyphosis.

“Length of stay is important in an era of value-based care; however, studies such as this one are concerned with more than reimbursement,” states Ryan Goodwin, MD, Director of Cleveland Clinic’s Center for Pediatric and Adolescent Orthopaedics. “The modifiable risk factors we identified, such as effective pain relief and major postoperative complications, relate to patient safety and well-being and overall quality of care.”

Identifying risks factors associated with extended length of stay

The study involved retrospective analysis of data from pediatric scoliosis patients (n = 407) undergoing surgical correction from January 1, 2009 through December 31, 2017. Researchers defined a short length of stay (SLOS) as fewer than four days, and a LLOS as four or more days.

Of the patients included in this single-institution study, 232 had SLOS, with a mean stay of 3 ±0.5 days. The remaining 175 patients had LLOS, with a mean stay of 6 ±2 days. Researchers looked at factors related to a patient’s demographics, comorbidities and preoperative measurements of scoliosis curve, as well as factors related to the surgery itself and any complications.

Advertisement

Among the demographic characteristics, only female sex had statistically significant associations with LLOS. Higher thoracic kyphosis was the only preoperative radiographic measurement to correlate with LLOS. Comorbidities had no statistically significant impact on LOS.

In terms of surgery-related characteristics and postoperative complications, which might be considered somewhat modifiable risk factors, operative time and the number of osteotomies had no significant impact on LOS. Patients in whom 7 ±2 levels were fused had SLOS compared to patients who had 9 ±2 levels fused.

Opportunity to make meaningful improvements in quality of care

In patients with major postoperative complications, such as the development of motor weakness, the need for transfusion, infection or reoperation, the risk of LLOS increased 11-fold. Patients without EA for pain control, a modifiable factor, had a three-fold increased risk of LLOS. Comorbidities, preoperative curve Cobb angle and number of osteotomies did not have a statistically significant impact on LOS.

Dr. Goodwin notes, “To our knowledge, this is the largest single-institution study, looking at the most comprehensive list of potential risk factors that might impact length of stay in this patient population. One day in a U.S. hospital can cost up to $4,000. Lowering these costs by reducing the number of in-hospital recovery days is good for everyone involved—patients, providers and payers.”

Advertisement

Related Articles

illustration of myelin sheaths wrapped around neuron axons
Revised McDonald Criteria for Multiple Sclerosis: A Big Step Toward Biomarker-Driven Diagnosis

A co-author of the new recommendations shares the updates you need to know

Dr. Jason Savage against a decorative background with podcast button overlay
October 2, 2025/Neurosciences/Podcast
Essentials of Revision Spine Deformity Surgery (Podcast)

Success for these complex operations requires judicious patient selection and presurgical patient optimization

physician talking with a patient in medical office
De-Escalation of Disease-Modifying Therapies in MS: A Real-World Look at Outcomes

Rebound risk is shaped by patient characteristics and mechanism of action of current DMT

woman speaking to a doctor
Tool Shows Promise for Individualized Decision Support on Stopping Disease-Modifying Therapy for Multiple Sclerosis

First-of-kind prediction model demonstrates high consistency across internal and external validation

health worker preparing infusion of injectable drug
Ocrelizumab Associated With Nearly Twofold Increase in Serious Infections Vs. Platform Injectables in Multiple Sclerosis

Real-world study also finds no significant rise in ocrelizumab-related risk with advanced age

two brain MRIs side by side with red circles on them
Cognitive Impairment in Multiple Sclerosis Linked to Rapid Thalamic Atrophy

Machine learning study associates discrete neuropsychological testing profiles with neurodegeneration

older woman lying with head on pillow looking vaguely unsettled
September 24, 2025/Neurosciences/Sleep Disorders
Sleep Disorders Increase Likelihood of Poor Functional Status in Neurological Populations

Study highlights value of sleep disorder screening and targeted management strategies

two brain MRIs side by side
Brain Volume Changes and Disability in MOGAD: Defining Differences From Other Demyelinating Diseases

Despite less overall volume loss than in MS and NMOSD, volumetric changes correlate with functional decline

Ad